Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528-1532.

Publikováno v: Blood [Blood] 2020 Apr 23; Vol. 135 (17), pp. 1507.

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.

Autor: Kuruvilla J; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Rushton C; Simon Fraser University, Burnaby, British Columbia, Canada., Villa D; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada., Aslam M; Hematology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Prica A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Abdel Samad N; Hematology, The Moncton Hospital, Moncton, New Brunswick, Canada., Doucet S; Hematologic Oncology, CHUM-Hopital Notre-Dame, Montreal, Quebec, Canada., Dudebout J; Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada., Fleury I; Hematologic Oncology, Maisonneuve Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada., Fraser G; Hematology, Juravinski Cancer Centre, Hamilton, Ontario, Canada., Larouche JF; CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada., Shafey M; Alberta Health Services, University of Calgary, Calgary, Alberta, Canada., Skrabek P; Section of Hematology/Oncology Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada., Skamene T; Jewish General Hospital, Montreal, Quebec, Canada., Morin RD; Simon Fraser University, Burnaby, British Columbia, Canada., Alcaide M; Simon Fraser University, Burnaby, British Columbia, Canada., Ben-Neriah S; BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada., Lee D; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Winch C; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Shepherd LE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Scott DW; BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada., Crump M; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Chen BE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada., Hay AE; Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 2067-2071. Date of Electronic Publication: 2024 Sep 12.

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2.

Autor: Collinge B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Hilton LK; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Alduaij W; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Tucker T; Cancer Genetics and Genomics Laboratory, BC Cancer, Vancouver, BC, Canada., Slack GW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Farinha P; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Craig JW; Department of Pathology, University of Virginia, Charlottesville, VA., Boyle M; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Meissner B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Villa D; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Gerrie AS; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Sehn LH; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Savage KJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Morin RD; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Mungall AJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada., Steidl C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Publikováno v: Blood [Blood] 2024 Oct 10; Vol. 144 (15), pp. 1611-1616.

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study).

Autor: Hilton LK; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Collinge B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Alduaij W; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Shaalan H; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Weng AP; Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada., Cruz M; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada., Slack GW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Farinha P; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Miyata-Takata T; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Boyle M; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Meissner B; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada., Cook JR; Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH., Ondrejka SL; Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH., Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany., Rosenwald A; Institute of Pathology, University of Wurzburg, Wurzburg, Germany., Campo E; Hematopathology Section, Hospital Clinic of Barcelona, Institut d'Investigaciones Biomediques August Pi I Sunyer, University of Barcelona, Barcelona, Spain., Amador C; Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL., Greiner TC; Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE., Raess PW; Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR., Song JY; Department of Pathology, City of Hope, Duarte, CA., Inghirami G; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY., Jaffe ES; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Weisenburger DD; Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE., Chan WC; Department of Pathology, City of Hope, Duarte, CA., Beiske K; Department of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Fu K; Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Delabie J; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Pittaluga S; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Iqbal J; Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE., Wright G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Sehn LH; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Savage KJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada., Mungall AJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada., Feldman AL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Staudt LM; Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Steidl C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada., Rimsza LM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ., Morin RD; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada., Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.; Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada.

Publikováno v: Blood [Blood] 2024 Aug 01; Vol. 144 (5), pp. 525-540.

Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.

Autor: Aoki T; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Princess Margaret Cancer Centre-University Health Network, Toronto, Ontario, Canada., Jiang A; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Xu A; Cedars-Sinai Medical Center, Los Angeles, CA., Yin Y; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Gamboa A; Cedars-Sinai Medical Center, Los Angeles, CA., Milne K; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Takata K; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.; Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Miyata-Takata T; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Chung S; Leukemia/Bone Marrow Transplant Program of BC, BC Cancer, Vancouver, British Columbia, Canada., Rai S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Wu S; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada., Warren M; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Strong C; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Goodyear T; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Morris K; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Chong LC; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Hav M; Cedars-Sinai Medical Center, Los Angeles, CA., Colombo AR; Cedars-Sinai Medical Center, Los Angeles, CA., Telenius A; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Boyle M; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Ben-Neriah S; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Power M; Leukemia/Bone Marrow Transplant Program of BC, BC Cancer, Vancouver, British Columbia, Canada., Gerrie AS; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Weng AP; Terry Fox Laboratory, BC Cancer, Vancouver, British Columbia, Canada., Karsan A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.; Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada., Roth A; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada., Farinha P; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Scott DW; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Savage KJ; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada., Nelson BH; Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada., Merchant A; Cedars-Sinai Medical Center, Los Angeles, CA., Steidl C; Centre for Lymphoid Cancer, BC Cancer, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 20; Vol. 42 (9), pp. 1077-1087. Date of Electronic Publication: 2023 Dec 19.